Canada Markets closed

Global Breast Cancer Diagnostics Market (2021 to 2028) - Size, Share & Trends Analysis Report

·8 min read

Dublin, Sept. 16, 2021 (GLOBE NEWSWIRE) -- The "Global Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Platform-based, Instrument-based), by Type (Imaging, Biopsy, Genomic Tests, Blood Tests), by Application, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The global breast cancer diagnostics market size is expected to reach USD 6.8 billion by 2028. The market is expected to expand at a CAGR of 7.0% from 2021 to 2028. The growth is largely attributable to the increasing geriatric population exposed to the risk of breast cancer and early detection coupled with increasing awareness about breast cancer.

The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth. This advanced technology can detect 40.0% more cancers than 2D mammograms and reduce patient recalls. Rapid technological advancements are a major factor expected to drive the market over the coming years.

Companies are adopting strategies that allow them to use their resources to aid in the development of new products, as well as enhance their supply chain. In November 2019, Exact Sciences Corporation announced the acquisition of Genomic Health, which was expected to help enhance the company's market position and offerings by acquiring its product portfolio. In January 2021, Hologic Inc. announced that it has agreed to acquire Biotheranostics for approximately US$ 230 million. Biotheranostics is a commercial-stage molecular diagnostics provider for breast and metastatic cancers.

The increasing launch of predictive and companion diagnostic tests for breast cancer is expected to boost the market growth. Recent launches in the segment include BRACAnalysis CDx by Myriad Genetics, which received FDA approval in 2018 as breast cancer companion diagnostics. In May 2019, QIAGEN introduced therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for Novartis proprietary PIQRAY in guiding treatment decisions from tissue and liquid biopsy.

In January 2019, the Fujifilm Holdings Corporation introduced its Tomosynthesis Biopsy option for ASPIRE Cristalle mammography system. This technique was expected to enable physicians to detect breast cancers more efficiently compared to others by providing an enhanced 3D image and a digital mammogram.

However, there are specific risk factors associated with these imaging procedures. They involve administering high doses of fluorescent and barium contrast agents, as well as radiation exposure in the case of imaging and endoscopic procedures, which can cause several adverse effects such as nausea or diarrhea. The risks of ionizing radiation exposure associated with the use of CT, MRI, and X-rays, as well as the use of radioactive tracer injections in PET can limit the adoption of such screening procedures. Therefore, factors such as adverse effects of imaging act as a challenge for the companies in this market.

Breast Cancer Diagnostics Market Report Highlights

  • The imaging segment held the largest revenue share in 2020 and the blood tests segment is expected to grow at the fastest rate

  • By product, the instrument-based products segment accounted for the largest revenue share in 2020 due to government initiatives such as mandatory screening in developed countries such as the U.S., Canada, and the U.K. for women above 45 years of age, increasing the overall testing and screening of breast cancer

  • The platform-based products segment is expected to witness the fastest growth over the forecast period. These tests are mostly used for assessing the efficacy of chemotherapy and targeted therapy in women

  • By application, the diagnostic and predictive segment dominated the market in 2020 and the prognostic segment is expected to witness the fastest CAGR over the forecast period due to increasing collaborations and efforts for advancements in diagnostics

  • The hospitals and clinics segment dominated the market in 2020

  • The medical labs and diagnostics centers segment is expected to witness the fastest CAGR over the forecast period due to an increase in platform-based testing such as NGS, and PCR

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Framework
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Increasing Incidence Of Breast Cancer
3.4.1.2 Technological Advancements
3.4.1.3 Favorable Reimbursement Framework For Breast Cancer Diagnosis
3.4.1.4 Early Detection And Increase In Awareness About Breast Cancer
3.4.2 Market Restraint Analysis
3.4.2.1 Adverse Effects Of Screening Procedures
3.5 Breast Cancer Diagnostics Market Analysis Tools
3.5.1 Pestel Analysis
3.5.2 Industry Analysis - Porter's

Chapter 4 Breast Cancer Diagnostics Market: Type Segment Analysis
4.1 Breast Cancer Diagnostics Market: Type Movement Analysis
4.2 Imaging
4.2.1 Imaging market, 2017 - 2028 (USD Million)
4.3 Biopsy
4.3.1 Biopsy market, 2017 - 2028 (USD Million)
4.4 Genomic Tests
4.4.1 Genomic tests market, 2017 - 2028 (USD Million)
4.5 Blood Tests
4.5.1 Blood tests market, 2017 - 2028 (USD Million)
4.6 Others
4.6.1 Others market, 2017 - 2028 (USD Million)

Chapter 5 Breast Cancer Diagnostics Market: Product Segment Analysis
5.1 Breast Cancer Diagnostics Market: Product Movement Analysis
5.2 Platform-based Products
5.2.1 Platform based products market, 2017 - 2028 (USD Million)
5.2.2 Next-generation sequencing
5.2.2.1 Next-Generation Sequencing market, 2017 - 2028 (USD Million)
5.2.3 Microarrays
5.2.3.1 Microarrays market, 2017 - 2028 (USD Million)
5.2.4 PCR
5.2.4.1 PCR market, 2017 - 2028 (USD Million)
5.2.5 Others
5.2.5.1 Others market, 2017 - 2028 (USD Million)
5.3 Instrument-based Products
5.3.1 Instrument-based products market, 2017 - 2028 (USD Million)
5.3.2 Imaging
5.3.2.1 Imaging market, 2017 - 2028 (USD Million)
5.3.3 Biopsy
5.3.3.1 Biopsy market, 2017 - 2028 (USD Million)

Chapter 6 Breast Cancer Diagnostics Market: Application Segment Analysis
6.1 Breast Cancer Diagnostics Market: Application Movement Analysis
6.2 Screening
6.2.1 Screening market, 2017 - 2028 (USD Million)
6.3 Diagnostic & Predictive
6.3.1 Diagnostic and predictive market, 2017 - 2028 (USD Million)
6.4 Prognostic
6.4.1 Prognostic market, 2017 - 2028 (USD Million)
6.5 Research
6.5.1 Research market, 2017 - 2028 (USD Million)

Chapter 7 Breast Cancer Diagnostics Market: End-use Segment Analysis
7.1 Breast Cancer Diagnostics Market: End-use Movement Analysis
7.2 Hospitals & Clinics
7.2.1 Hospitals & clinics market, 2017-2028 (USD Million)
7.3 Diagnostic Centers and Medical Laboratories
7.3.1 Diagnostic centers and medical laboratories market, 2017-2028 (USD Million)
7.4 Others
7.4.1 Others market, 2017-2028 (USD Million)

Chapter 8 Breast Cancer Diagnostics Market: Segment Analysis, By Region, 2017-2028 (USD Million)

Chapter 9 Breast Cancer Diagnostics Market: Competitive Analysis
9.1 Recent developments and impact analysis, by key market participants
9.1.1 Ansoff Matrix
9.2 Company Categorization
9.2.1 Innovators
9.2.2 Market Leaders
9.3 Vendor Landscape
9.3.1 List Of Key Distributors And Channel Partners
9.3.2 Key Customers
9.3.3 Key Company Market Share Analysis, 2020
9.4 Public Companies
9.4.1 Company Market Position Analysis
9.4.2 Competitive Dashboard Analysis
9.4.2.1 Market Differentiators
9.5 Private Companies
9.5.1 List Of Key Emerging Companies
9.6 Major Deals and Strategic Alliances Analysis
9.6.1 New Product Launches
9.6.2 Joint Ventures
9.6.3 Acquisitions
9.6.4 Licensing And Partnerships
9.6.5 Conferences And Campaigns
9.7 Company Profiles
9.7.1 KONINKLIJKE PHILIPS N.V.
9.7.1.1 Company overview
9.7.1.2 Financial performance
9.7.1.3 Product benchmarking
9.7.1.4 Strategic initiatives
9.7.2 DANAHER CORPORATION
9.7.2.1 Company overview
9.7.2.2 Financial performance
9.7.2.3 Product benchmarking
9.7.2.4 Strategic initiatives
9.7.3 HOLOGIC INC
9.7.3.1 Company overview
9.7.3.2 Financial performance
9.7.3.3 Product benchmarking
9.7.3.4 Strategic initiatives
9.7.4 BECTON, DICKINSON AND COMPANY
9.7.4.1 Company overview
9.7.4.2 Financial performance
9.7.4.3 Product benchmarking
9.7.4.4 Strategic initiatives
9.7.5 QIAGEN
9.7.5.1 Company overview
9.7.5.2 Financial performance
9.7.5.3 Product benchmarking
9.7.5.4 Strategic initiatives
9.7.6 THERMO FISHER SCIENTIFIC, INC.
9.7.6.1 Company overview
9.7.6.2 Financial performance
9.7.6.3 Product benchmarking
9.7.6.4 Strategic initiatives
9.7.7 GENOMIC HEALTH (EXACT SCIENCES)
9.7.7.1 Company overview
9.7.7.2 Financial performance
9.7.7.3 Product benchmarking
9.7.7.4 Strategic initiatives
9.7.8 MYRIAD GENETICS, INC.
9.7.8.1 Company overview
9.7.8.2 Financial performance
9.7.8.3 Product benchmarking
9.7.8.4 Strategic initiatives
9.7.9 ARGON MEDICAL DEVICES INC.
9.7.9.1 Company overview
9.7.9.2 Product benchmarking
9.7.9.3 Strategic initiatives
9.7.10 F. HOFFMANN-LA ROCHE LTD
9.7.10.1 Company overview
9.7.10.2 Financial performance
9.7.10.3 Product benchmarking
9.7.10.4 Strategic initiatives

For more information about this report visit https://www.researchandmarkets.com/r/881zwa

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting